DHR · Danaher Corporation
$232.97
+1.07% last session
End-of-day data · close of 2026-10-26
Market cap
$164B
Enterprise value
$186B
Trailing P/E
38.6
Forward P/E
25.0
Dividend yield
1.0%
Beta
0.80
Avg volume
4M
Employees
58K
Daily Change %
1.07%
5 Days Change
1.40%
10 Days Change
1.72%
30 Days Change
3.96%
60 Days Change
8.01%
Month to Day Change
10.02%
Year to Day Change
2.38%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — DHR
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-22
Latest call per bank · past 12 months
Citigroup
Buy$270
+15.9% vs priceBarclays
Overweight$260
+11.6% vs priceJP Morgan
Overweight$270
+15.9% vs priceMorgan Stanley
Overweight$240
+3.0% vs priceRBC Capital
Outperform$250
+7.3% vs priceWells Fargo
Equal-Weight$195
-16.3% vs priceHSBC
Buy$230
-1.3% vs priceUBS
Buy$250
+7.3% vs priceGoldman Sachs
Buy$230
-1.3% vs priceJefferies
Buy$265
+13.7% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-22 | Citigroup | Maintains | Buy | $230 → $270 |
| 2026-10-22 | Barclays | Maintains | Overweight | $255 → $260 |
| 2026-10-22 | JP Morgan | Maintains | Overweight | $250 → $270 |
| 2026-10-22 | TD Cowen | Maintains | Buy | $255 → $270 |
| 2026-10-22 | Stifel | Maintains | Buy | $220 → $260 |
| 2026-10-22 | Baird | Maintains | Outperform | $246 → $254 |
| 2026-10-13 | Morgan Stanley | Maintains | Overweight | $220 → $240 |
| 2026-10-13 | TD Cowen | Maintains | Buy | $236 → $255 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-26
- neutral: RSI (14): RSI is 62 — neutral momentum, neither overbought nor oversold.
- bullish: Price vs 50-day MA: Trading 7.6% above the 50-day MA ($216.51).
- bullish: Price vs 200-day MA: Trading 16.2% above the 200-day MA ($200.52).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.55) — short-term momentum is improving.
- bullish: 52-week range: Price is within 5% of the 52-week high ($240.61).
DHR Price Chart
Loading chart for DHR…
Fundamentals
About Danaher Corporation
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.
More in Diagnostics & Research
TMO
Thermo Fisher Scientific Inc
$253B 18.5% YTD
NTRA
Natera, Inc.
$58B 76.7% YTD
A
Agilent Technologies, Inc.
$50B 30.3% YTD
IQV
IQVIA Holdings, Inc.
$45B 21.4% YTD
IDXX
IDEXX Laboratories, Inc.
$45B -15.7% YTD
WAT
Waters Corporation
$45B 20.1% YTD
ILMN
Illumina, Inc.
$41B 106.7% YTD
MTD
Mettler-Toledo International, I
$33B 19.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.